In SCCHN, the FGFR3-TACC3 fusion was identified and FGFR mutations were studied mainly in HPV-positive cases [6, 16, 17], suggesting this RTK may serve as a target for treatment in this specific SCCHN population. Here, FGFR3 is linked to head and neck squamous cell carcinoma.